Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The efficacy of prophylactic cranial irradiation (PCI) is still controversial in small cell lung cancer (SCLC) patients with pT1-2N0M0 disease after complete resection. The majority of previous studies haven't discerned the potential benefit of PCI in this subgroup of patients, probably due to the paucity of these patients and distinct treating modalities. The aim of this study is to demonstrate the potential medical benefit of PCI in these patients.
Methods: A retrospective study was conducted to evaluate the potential benefit of PCI in pT1-2N0M0 SCLC patients after complete resection. We retrospectively reviewed 112 pT1-2N0M0 SCLCs after complete resection and adjuvant chemotherapy between January 2013 and January 2022. Survival and Cox regression analysis were conducted to elucidate the potential medical benefit of PCI in these patients.
Results: The median overall survival (OS) has not been reached. The 2-year, 5-year, 8-year OS rate was 93.7%, 73.2%, and 65.7%, respectively. Brain metastasis (BM) was observed in 17.0% (19/112) patients during the process of follow-up. PCI significantly decreased the BM actuarial risk from 23.9 to 4.9% (log-rank p = 0.0097, HR = 0.180, 95% CI: 0.041-0.778). The brain metastasis free survival (BMFS, log-rank p = 0.02) and OS (log-rank p = 0.05) in PCI cohort were also significantly longer than that of non_PCI group. Cox analysis demonstrated that PCI was an independent prognostic factor in both BM actuarial risk (HR = 0.198, 95% CI: 0.046-0.859, p = 0.031) and BMFS (HR = 0.387, 95% CI: 0.169-0.890, p = 0.025). Moreover, T2 patients showed a significant superior prognosis in terms of BM actuarial risk with comparison to those with T1 disease in non_PCI cohort (log-rank p = 0.016, HR = 3.345, 95% CI: 1.177-9.511), whereas the difference could not be observed in PCI cohort.
Conclusions: PCI was significantly associated with a better clinical outcome in pT1-2N0M0 SCLC patients who received complete resection and adjuvant chemotherapy, especially in T2 patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11829441 | PMC |
| http://dx.doi.org/10.1186/s12885-025-13667-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Optimizing Robotic Spleen-Preserving Distal Pancreatectomy: Strategies and Innovations to Enhance Safety and Efficacy.
Ann Surg Oncol
September 2025
Hepato‑Biliary and Pancreatic Surgery Unit, Department of Surgery, Hospital del Mar, Pompeu Fabra University, Barcelona, Spain.
Background: Spleen-preserving distal pancreatectomy by robotic surgery is a safe and feasible surgical technique. Currently, spleen-preserving distal pancreatectomy represents an alternative to the classical distal pancreatectomy with splenectomy, in the case of benign and low-grade malignant diseases of the body or pancreas tail. The reasons for preserving the spleen are based on the reduction of postoperative complications, such as post-splenectomy infections, subphrenic abscess, portal thrombosis, pulmonary hypertension, thrombocytosis, and thromboembolism.
View Article and Find Full Text PDF[Minimally invasive surgery for liver echinococcosis].
Khirurgiia (Mosk)
September 2025
Dagestan State Medical University, Makhachkala, Russia.
Objective: To analyze the effectiveness of minimally invasive surgery for small and medium sized liver cysts.
Material And Methods: We used minimally invasive technologies in 331 patients with echinococcal liver cysts (small cysts (<3.5 cm) - 49 (14.
Real-world outcomes of neoadjuvant chemoimmunotherapy in patients with nonsmall cell lung cancer: Predictors of surgery, pathologic complete response, and event-free survival.
Cancer
September 2025
Thoracic Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA.
Background: Trials of neoadjuvant chemoimmunotherapy (chemoIO) have changed the standard of care for resectable nonsmall cell lung cancer (NSCLC). This study characterizes the outcomes of off-trial patients who received treatment with neoadjuvant chemoIO.
Methods: The authors analyzed records of patients with stage IB-III NSCLC who received neoadjuvant chemoIO with an intent to proceed to surgical resection at three US academic institutions.
Successful treatment of localized Merkel cell carcinoma with avelumab in a patient with amyotrophic lateral sclerosis.
Immunotherapy
September 2025
Department of Dermatology and Allergology, University Hospital, LMU Munich, Munich, Germany.
Currently, the first-line treatment of non-metastatic Merkel cell carcinoma (MCC) is complete resection. In case of unresectable or metastatic MCC, immune checkpoint inhibitor (ICI) therapy with avelumab (or in the US also pembrolizumab or retifanlimab) is indicated. We report on a patient with a primary, non-metastatic MCC on the left eyelid and amyotrophic lateral sclerosis (ALS).
View Article and Find Full Text PDFBertolotti Syndrome in the Pediatric Population: A Literature Review and Management Algorithm.
J Am Acad Orthop Surg Glob Res Rev
September 2025
From the Harvard Medical School, Boston, MA (Gabriel, Hines, and Prabhat); the Lenox Hill Hospital, New York, NY (Dr. Ang); and the Boston Children's Hospital, Department of Orthopedic Surgery, Boston, MA (Dr. Liu and Dr. Hogue).
Purpose: The purpose of this study was to develop a comprehensive step-wise management algorithm for Bertolotti syndrome in the pediatric population by conducting a systematic review of the current literature regarding the diagnostic evaluation, nonsurgical and surgical treatment, and outcomes.
Methods: A systematic review of the literature was conducted using PubMed to identify studies focused on the management of Bertolotti syndrome in the pediatric population. Data extraction of clinical presentation, management strategies, imaging, and outcomes was completed.